PHIA Koninklijke Philips N.V.

Philips completes cancellation of 3.8 million shares

Philips completes cancellation of 3.8 million shares

June 25, 2020

Amsterdam, the Netherlands – (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 3,809,675 of its shares. The cancelled shares were acquired as part of Philips’ EUR 1.5 billion share repurchase program that started in the first quarter of 2019. Further details on the repurchase program can be found .

Philips’ current issued share capital amounts to EUR 178,594,560.60 representing 892,972,803 common shares.

For further information, please contact:

Ben Zwirs

Philips Global Press Office

Tel.:

E-mail:

Derya Guzel

Philips Investor Relations

Tel.:

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

EN
25/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips unveils Rembra CT at ECR 2026, setting a new benchmark for spe...

Philips unveils Rembra CT at ECR 2026, setting a new benchmark for speed and patient access designed to support diagnostic confidence for acute and high-demand imaging environments March 4, 2026 CE Marked and 510(k) pending, Rembra’s advanced image reconstruction technology delivers up to 106 images per second [1] and a high throughput of up to 270 patients per day [2] to support faster diagnosis by making scans available in near-real timeWith the largest-in-class 85 cm bore, Rembra accommodates challenging patient types, providing more access for complex interventions, bariatric imaging a...

 PRESS RELEASE

Philips publishes its Annual Report 2025

Philips publishes its Annual Report 2025 February 19, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course. Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to f...

 PRESS RELEASE

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI ...

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort February 12, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality i...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch